Breast Cancer Trials (BCT) is a world leading clinical trials research organisation, dedicated to finding new and better treatments and prevention strategies for people affected by this disease.
Our research program involves multicentre national and international clinical trials and brings together more than 835 researchers in 109 institutions throughout Australia and New Zealand. BCT has contributed to almost 1,230 peer reviewed publications and more than 16,800 women have participated in our breast cancer clinical trials.
The 2023 ASM will also host a number of internationally renowned guest speakers including key BCT researchers. Delegates include leading Australian and New Zealand medical practitioners and clinicians, and clinical trials management personnel.
The full and extensive program will include two days of scientific sessions covering timely reviews of breast cancer clinical trials, discussion of new protocols, future clinical trials research and other research developments.
We look forward to an in-person meeting, offering the opportunity for us all to connect in Auckland, New Zealand. For up to date information on COVID-19 in New Zealand, including travel requirements, click here.
Please note that the 2023 FIFA Women’s World Cup will be in Auckland from Thursday 20 July – Sunday 20 August 2023.
The Breast Cancer Trials ASM is not open to the general public to attend.
Attracting leading health professionals involved in the conduct of breast cancer clinical trials throughout Australia and New Zealand, the Breast Cancer Trials Annual Scientific Meeting is an important event to stay up-to-date on research and to network with colleagues.
Please note that the Trials Coordination Forum is primarily for Trial/Study Coordinators; not suitable for Pharmaceutical representatives.
Our New Concept Workshop will be held at the Annual Scientific Meeting (ASM) to provide an opportunity for Breast Cancer Trials (BCT) members and non-members to present new research ideas.
The workshop will be held at The Cordis, Auckland, and will involve a presentation of selected concepts, followed by discussion and feedback from the audience.
More information to come early in the New Year.
Symposium 1 is sponsored by Gilead.
Supportive Care.
Symposium 2 is sponsored by AstraZeneca.
Early Breast Cancer.
Please note, this meeting is for BCT members only.
The conference dinner is sponsored by AstraZeneca.
Symposium 1 is sponsored by Gilead.
Advanced Breast Cancer.
Oncoplastic Breast Surgery.
Symposium 2 is sponsored by MSD.
Translational Research.
Chair of the German Breast Group (GBG), and Professor of obstetrics and gynecology at the Goethe University of Frankfurt.
Professor Sibylle Loibl is Chair of the German Breast Group (GBG) and the Chief Executive Officer of the GBG Forschungs GmbH. She is a Professor of obstetrics and gynecology at the Goethe University of Frankfurt.
Professor Loibl gained a doctorate at the Ruprecht Karl University of Heidelberg and trained as a consultant in gynaecology and obstetrics at the women’s clinics of the university hospitals in Heidelberg and Frankfurt am Main.
She devotes most of her time to clinical research within the German Breast Group and clinical work at the Centre for Haematology and Oncology, Bethanien in Frankfurt. Professor Loibl has gained international renommée for her research in neoadjuvant breast cancer, breast cancer during pregnancy and breast cancer in young women.
She established the Translational Research Group within the German Breast Group and has headed numerous research projects. In addition, Prof. Dr. Loibl has been involved in conducting and managing a significant number of national and international, practice changing clinical trials.
She is author of more than 400 original and peer review articles and scientific papers; she has written numerous books and book chapters.
Radiation Oncologist at Iridium Netwerk and the University of Antwerp in Belgium, where he completed his medical studies.
Professor Philip Poortmans is a Radiation Oncologist at Iridium Netwerk and University of Antwerp in Belgium.
He completed his medical studies at the University of Antwerp and was trained as a Radiation Oncologist at the Middelheim and Vincentius Hospitals in Antwerp.
His research interests include breast cancer, FLASH radiation therapy, IOeRT, malignant lymphoma and rare tumours. Professor Poortmans is the Past-Present of ESTRO, where he is currently the Course Director of the teaching courses “Multidisciplinary Management of Breast Cancer” and “Accelerated Partial Breast Irradiation”, and the liaison for multidisciplinary courses.
He has edited numerous book chapters and co-edited two books.
Professor Poortmans received the Jens Overgaard Award from ESTRO in 2019 and the Klaas Breur Award from ESTRO in 2020. In 2021 he received the St Gallen Breast Cancer Award.
Co-chair of the NCI BOLD Taskforce, the SWOG translational medicine breast group and the TBCRC locoregional working group.
Professor Alastair Thompson graduated with distinction in surgery from the University of Edinburgh.
He trained and practiced in Scotland as a clinician-scientist focused on multidisciplinary patient care alongside translational “bench to bedside” studies and innovative clinical trials in cancer in Dundee, UK.
He chaired the NCRI Breast Clinical Studies Group, led the Breast Cancer Campaign/Breast Cancer Now tissue bank and engaged in a range of pivotal roles in key drug, radiation therapy and surgical trials involving the UK, Europe, the United States, Australia and New Zealand.
Since moving to the US in 2014, initially to MD Anderson as Professor of Surgery, he is now Olga Keith Weiss Professor of Surgery and Associate Director of the Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine.
He co-chairs the NCI BOLD Taskforce, the SWOG translational medicine breast group, the TBCRC locoregional working group and is an active member and regular presenter at SSO, ASBrS, ASCO and AACR.
With successful peer reviewed funding from US government and international charitable sources spanning laboratory to clinical studies, successful supervision of 24 postgraduate students and over 400 publications in the highest impact factor clinical and scientific journals, his key mission remains improving care for those with cancer.
If you are interested in becoming a sponsor at Breast Cancer Trials 44th Annual Scientific Meeting, please email asm@bctrials.org.au.
The ASM Secretariat is responsible for conference registration only and delegates are responsible for their accommodation. You can book your accommodation at The Cordis Hotel, Auckland here.
Alternatively, there are several hotels within walking distance to The Cordis Hotel.